Time filter

Source Type

Ramsgate, United Kingdom

Haynes J.J.,Sandwich Laboratories | Jones H.,Sandwich Laboratories | Gibson D.,Sandwich Laboratories | Clark G.T.,Sandwich Laboratories
Bioanalysis | Year: 2011

Background: Targeting the gonadotropin-releasing hormone pathway for the treatment of endometriosis leads to an interest in monitoring for endogenous modulators of this pathway (RFRP3 and kisspeptin) as baseline controls for treatment development. Results: Stabilization of RFRP3 was shown to be extremely difficult in a highly enzymatically active matrix, such as rat blood. Sample denaturing with solvent at collection was necessary due to enzyme inhibition being unsuccessful at stabilization leading to difficulties in sample processing. Monitoring multiple fragments formed in blood can aid in profiling these peptides once in-source conversion is controlled. Conclusion: generic high-sensitivity LC-MS/MS assay was developed for RFRP3 and the fragments formed from it in whole blood. Use of 2D chromatography circumvents concentration and retention issues related to small fragments with a normal flow setup, making a more open-access approach feasible. © 2011 Future Science Ltd. Source

Glossop P.A.,Sandwich Laboratories | Watson C.A.L.,Sandwich Laboratories | Price D.A.,Sandwich Laboratories | Price D.A.,Pfizer | And 26 more authors.
Journal of Medicinal Chemistry | Year: 2011

A novel tertiary amine series of potent muscarinic M 3 receptor antagonists are described that exhibit potential as inhaled long-acting bronchodilators for the treatment of chronic obstructive pulmonary disease. Geminal dimethyl functionality present in this series of compounds confers very long dissociative half-life (slow off-rate) from the M 3 receptor that mediates very long-lasting smooth muscle relaxation in guinea pig tracheal strips. Optimization of pharmacokinetic properties was achieved by combining rapid oxidative clearance with targeted introduction of a phenolic moiety to secure rapid glucuronidation. Together, these attributes minimize systemic exposure following inhalation, mitigate potential drug-drug interactions, and reduce systemically mediated adverse events. Compound 47 (PF-3635659) is identified as a Phase II clinical candidate from this series with in vivo duration of action studies confirming its potential for once-daily use in humans. © 2011 American Chemical Society. Source

Discover hidden collaborations